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 ABSTRACT 
In this study, actoprotector activity of 1,2,4-triazole derivatives is described. 
The biological activity of synthetic 4-R-(ideneamino)-5-R-4Н-1,2,4-triazole-3-
thiols was analyzed. The forced swim test with a weight load of 10% of the test 
animal’s body weight was applied. According to the obtained results, 
compounds that contained NH4+ and CuSO4 substituents were among the 
most active, potency of which was close to that of the reference drug Riboxin. 
Introduction of propylamine, isopropylamine and piperazine groups into the 
molecule decreases the actoprotector activity. Compounds containing 
monoethanolamine, diethylamine, ethylamine, and magnesium sulfate moieties 
almost did not exhibit actoprotector activity. 
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Fast pace of life people have nowadays often leads to mental and physical exhaustion. A great 
portion of people, especially those living in cities, have now regularly begun to experience chronic 
fatigue syndrome, which involves systemic decrease of adaptive defense mechanisms, work 
productivity, and immunity. This issue is pertinent to athletes who experience fatigue from physical 
exercises almost every day. The main reason behind the mentioned symptoms is continuous physical 
and mental loads of high and moderate intensity. In such cases, when rest cannot resolve these issues, 
physicians may prescribe actoprotectors. 
The use of modern medications, which exhibit actoprotector properties, is a promising and 
effective solution for the enhancement of physical and mental productivity [1]. Various groups of 
medications are available to address fatigue, ranging from synthetic drugs (Mexidol, Mildronate, 
Bromantane, Chlodantal, etc.), vitamin products of plant and animal origin (Eleutherococcus, 
Echinacea purpurea and others), and pill dosage forms (Ecdisten, Immunal) [2]. However, the effect 
on physical performance becomes apparent only in several weeks after the beginning of the treatment, 
which creates inconveniences when fatigue must be overcome quickly. 
In order to preclude this problem, an emerging class of low-toxic compounds may be used to 
stimulate productivity, which is actoprotectors [3,4]. Medicinal products of this class do not obstruct 
external respiratory and cardiovascular functions, stimulate physical productivity, and prevent fatigue. 
Heterocyclic systems pose great interest in this regard, and low-toxic 1,2,4-triazole derivatives hold a 
prominent place among them, particularly due to their antiviral, diuretic, anxiolytic, antitumor, and 
other biological effects [5-7]. 
Purpose. 
Study the actoprotector activity of various 4-R-(ideneamino)-5-R-4Н-1,2,4-triazole-3-thiols. 
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Materials and methods. The experiment was conducted on a group of outbred white rats with 
body weights within 135-319 g. The forced swim test (FST) with a weight load of 10% of the test 
animal’s body weight was applied [8]. Weight load was attached to the tailsets of the animals. 
Swimming was continued until exhaustion, which was recorded at 10 seconds after the animals were 
placed in the water. Each rat was placed into a separate water tank with water level of 60 cm. Water 
temperature was 24–27°С. The studied compounds and reference substance Riboxin were 
administered abdominally at the dose of 100 mg/kg in 20 minutes before FST [9]. The substances 
were administered at the dose of 1/10 of LD50 [10]. Swim time was recorded in seconds. For reference, 
a control group of animals was used, which received normal saline in 20 min prior to the test. 
 
Table 1. 
Compound no. Kat+ 
1.  C4H10NO+ 
2.  HO-CH2CH2-NН3+ 
3.  C4H12N 
4.  C2H5NH3+ 
5.  NH4+ 
6.  K+ 
7.  Na+ 
8.  1/3Fe3+ 
9.  1/2Mg2+ 
10.  1/2Cu2+ 
11.  C5H12N 
12.  CH3NH3+ 
13.  C5H12NO 
14.  C12H15N3O 
15.  C3H10N 
16.  1/2Zn2+ 
17.  C3H10N 
18.  (CH4)2NH+ 
19.  C4H11N2 
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Results and discussion. 
Actoprotector activity of 19 new compounds was studied. It was established that 4-R-
(ideneamino)-5-R-4Н-1,2,4-triazole-3-thiols exhibit actoprotector effect in range between 34.28% and 
12.86% as compared to the reference (Table 2). 
Table 2. 
No. Compound Forced swimming duration, s Δ% 
I. Control 
(normal saline) 
235.43  15.588  
II. Riboxin 277.00  11.745 17.66 
III. КП-56 253.00  8.106 7.46 
IV. КП-57 154.71  6.335 -34.28 
V. КП-58 258.86 12.512 9.95 
VI. КП-59 209.29  6.778 -11.10 
VII. КП-60 265.71  14.138 12.86 
VIII. КП-61 258.00  8.861 9.59 
IX. КП-62 261.14  6.595 10.92 
X. КП-63 260.14  6.638 10.50 
XI. КП-64 155.57  6.218 -33.92 
XII. КП-65 265.57  9.459 12.80 
XIII. КП-82 242.57  11.633 3.03 
XIV. КП-83 260.71 12.440 10.74 
XV. КП-92 257.71  6.046 9.47 
XVI. КП-93 249.57  14.328 6.01 
XVII. КП-94 262.86  9.349 11.65 
XVIII. КП-95 243.71  11.718 3.52 
XIX. КП-96 262.86 7.022 11.65 
XX. КП-97 243.71 11.718 3.52 
XXI. КП-98 263.29  6.736 11.83 
Science Review                                                                                                      ISSN 2544-9346 
 
26 9(26), November 2019                                                                                  
 
According to the obtained results, compounds containing NH4+ and CuSO4 substituents are among 
the most active, effect of which is close to that of the reference drug Riboxin. Introduction of propylamine, 
isopropylamine and piperazine groups into the molecule decreases the actoprotector activity. 
Introduction of such radicals as NaHCO3, FeCl3, КНСО3, and such substituents as 
methylamine and 4-methylmorpholine lowers the actoprotector activity of 2-(((3-mercapto-5-methyl-
4H-1,2,4-triazol-4-yl)imino)methyl)benzoic acid. 
Compounds (КП-56, КП-82, КП-93, КП-95, КП-97) have a slightly weaker actoprotector 
activity. At the same time, substances containing monoethanolamine, diethylamine, ethylamine, and 
MgSO4 moieties almost do not exhibit actoprotector activity. 
Conclusions. 
Nineteen new synthetic 4-R-(ideneamino)-5-R-4H-1,2,4-triazole-3-thiol derivatives were studied. 
It was found that compounds that have NH4+ and CuSO4 in its structure are the most potent 
actoprotectors. 
Compounds IV, V, VI, and XI do not exhibit any actoprotector activity. 
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